Today Boston Scientific announced its Q2 2013 results. CRM sales were 3% down from $488M for Q2 2012 to $475M this year (2% on constant-currency basis).
Neuromodulation went up by a whopping 21% from last year’s Q2 $91M to $111 in Q2 2013. The press release indicated that Boston Scientific achieved global year-over-year revenue growth of 21 percent in Neuromodulation on the strength of the Precision Spectra™ Spinal Cord Stimulator (SCS) System launch.